| Melissa Suzanne Kinser, PSY PHD | |
|
3 S Hill St, Athens, TN 37303-4289 | |
| (423) 622-1551 | |
| (877) 856-7133 |
| Full Name | Melissa Suzanne Kinser |
|---|---|
| Gender | Female |
| Speciality | Psychologist - School |
| Location | 3 S Hill St, Athens, Tennessee |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437665072 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TS0200X | Psychologist - School | 3074 (Tennessee) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Melissa Suzanne Kinser, PSY PHD Po Box 8114, Chattanooga, TN 37414-0114 Ph: (423) 622-1551 | Melissa Suzanne Kinser, PSY PHD 3 S Hill St, Athens, TN 37303-4289 Ph: (423) 622-1551 |
News Archive
Epitomics, Inc., a biotechnology company commercializing the next generation of antibodies based on its groundbreaking Rabbit Monoclonal technology, today announced the Company has now launched 23 novel cancer-related antibodies that were developed through a partnership with the National Cancer Institute's Center for Cancer Research.
Despite the well-known benefits of having a lifestyle that includes physical activity, eating a diet high in fruits and vegetables, maintaining a healthy weight, moderate alcohol use and not smoking, only a small proportion of adults follow this healthy lifestyle pattern, and in fact, the numbers are declining, according to an article published in the June 2009 issue of The American Journal of Medicine. Lifestyle choices are associated with the risk of cardiovascular disease as well as diabetes.
Today, the U.S. Food and Drug Administration issued the first marketing denial orders (MDOs) for electronic nicotine delivery system (ENDS) products after determining the applications for about 55,000 flavored ENDS products from three applicants lacked sufficient evidence that they have a benefit to adult smokers sufficient to overcome the public health threat posed by the well-documented, alarming levels of youth use of such products.
Researchers have confirmed that neuropeptide somatostatin can improve cognitive function in the brain. A research group of Professor Seung-Hee Lee from the Department of Biological Sciences at KAIST found that the application of neuropeptide somatostatin improves visual processing and cognitive behaviors by reducing excitatory inputs to parvalbumin-positive interneurons in the cortex.
AccessClosure Inc., the market leader in extravascular care technology, has commercially launched its Mynx Ace Vascular Closure Device, a safe and secure vascular closure product that provides consistent results with a new, easy-to-use deployment system to seal femoral artery access sites.
› Verified 4 days ago